Company Overview

Cerene Biomedics is an early stage start-up focusing on developing a new cooling therapy to treat patients suffering from epilepsy.  Approximately three million Americans have epilepsy; 200,000 new cases are diagnosed annually in the United States alone . Although anti-convulsants have been used to control the disease and reduce the severity and occurrence of seizures, one-third of individuals with epilepsy do not adequately respond to medication or may experience severe side effects.  Recent research shows targeted cooling to the surface of the brain reduces seizures in patients refractory to conventional therapy and has been shown to be safe in long term studies.


Epilepsy Facts¹:

  • Epilepsy and seizures affect over 3 million Americans of all ages, at an estimated annual cost of $15.5 billion in direct and indirect costs.
  • Approximately 200,000 new cases of seizures and epilepsy occur each year.
  • Ten percent of the American population will experience a seizure in their lifetime.
  • Three percent will develop epilepsy by age 75.